logo
Alberta researcher brings mental health first-aid training to Ottawa's Black community

Alberta researcher brings mental health first-aid training to Ottawa's Black community

Globe and Mail25-05-2025
Noah Boakye-Yiadom first had the idea for a specialized mental health first-aid training program for Black communities while in rural Alberta in 2018.
The Alberta Health Services researcher was leading a session for a Hutterite community when he was struck by the cultural differences his training needed to address. Black communities similarly need specific training for administering mental health care.
Mr. Boakye-Yiadom designed a mental health first-aid program that uses culturally respectful case scenarios rooted in Black experiences. The training course, which comes with a certification from the Mental Health Commission of Canada, is similar to a First Aid/CPR course.
Since 2022, the project has trained more than 400 Black people in Winnipeg, Calgary, Edmonton, Toronto, Red Deer and Fredericton.
Now, the one-day program will be held across Ottawa.
The goal is to help community members recognize when a friend or loved one is experiencing a mental health crisis and know how to respond.
According to the MHCC, mental health first-aid is immediate support for someone experiencing a mental problem or crisis – just as physical first-aid is offered before medical care. It is provided until professional help is available, or the crisis passes.
'We didn't alter the certification or redesign the entire program,' Mr. Boakye-Yiadom said of his existing mental health first-aid training program. 'Instead, we tailored the examples to reflect the lived realities of Black individuals. To achieve this, we engaged Black therapists, social workers, instructors and psychiatrists to review and contribute to the content.'
There is growing evidence of disproportionately high rates of mental illness among Black Canadians. A 2020 Statistics Canada survey found that 32 per cent of Black respondents reported symptoms of anxiety, compared with 24 per cent of their white counterparts.
The training program – developed in collaboration with Opening Minds, a branch of the MHCC funded by the Public Health Agency of Canada through the Ghanaian Canadian Association of Ontario – is designed to preserve life in situations where someone may pose a risk to themselves or others, and to help prevent mental health issues from escalating.
Denise Waligora, a training and delivery specialist for mental health first-aid at Opening Minds, said the course is vital even for those not in the Black community.
'The training gives participants a chance to practice using a conversation guide to approach, assess and assist,' she said. 'We listen without judgment, communicate with care, offer reassurance and information and encourage people to seek support – and we stress the importance of self-care for the first aider, too.'
She said as part of the course, participants work through practical scenarios, such as signs of depression or anxiety, and crisis scenarios such as suicidal thoughts or behaviour, reactions to traumatic events, panic attacks and overdoses.
Ms. Waligora said the training uses relatable scenarios to help participants apply their skills in situations they might realistically encounter or recognize in others.
'The course is about increasing mental health knowledge, recognizing when someone may be in decline, and responding with safe, respectful conversations,' she said. 'Being a mental health first-aider means being prepared to notice the signs and reach out in a meaningful way.'
Sharon Roberts, one of the training co-ordinators in Ottawa, said that if she had received early care during her own mental health crisis, she might have begun treatment much sooner.
'I did not know I had a mental illness. I didn't recognize the signs until I hit rock bottom,' said Ms. Roberts, who now works as a Black peer support worker at the Royal Ottawa Mental Health Centre.
She added that having access to mental health first-aid at the time could have made a significant difference. 'It might have at least given me a fighting chance,' she said. 'I think I would have sought help – especially for my children's sake.'
Ms. Roberts shared that she struggled with low-grade depression, known as dysthymia.
'It's so hard to live with,' she said, tears streaming down her cheeks. 'When it comes to illnesses like diabetes or cancer, people talk openly. But with mental illness, you're pushed aside – people turn away.'
Ms. Roberts said her work is rooted in empathy and connection. 'My job is about meeting people where they're at. Through my experience, I may not understand everything, but I can relate – and that connection allows us to support each other.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bruce Power gets funding to increase cancer-fighting isotope production
Bruce Power gets funding to increase cancer-fighting isotope production

CTV News

time18 minutes ago

  • CTV News

Bruce Power gets funding to increase cancer-fighting isotope production

Production of medical isotopes at the Bruce Power Nuclear Plant near Kincardine, Ont. is seen in this undated image. (Source: Bruce Power) Domestic supply chains for medical isotope production in Canada has received a boost from the federal government. Announced on Tuesday, the investment of up to $35 million over five years will support the project at the Bruce Power Nuclear Plant facility in Tiverton, Ont. According to the federal government, this next phase will see the installation of a second isotope production system (IPS) at Bruce Power's CANDU Unit 6 reactor, which will allow for a significant increase in the plant's ability to produce the medical isotope lutetium-177, used in targeted cancer therapies. 'Canada is proud to support research and development on medical isotopes... With this investment, we will continue to play a leading role in the global supply of medical isotopes and drive the creation of innovative health care treatments for Canadians,' said Minister of Health, Marjorie Michel. BRUCE POWER - ISOTOPES - AUG 2025 Officials make an announcement at Bruce Power on Aug. 19, 2025. (Scott Miller/CTV News London) Medical isotopes are used by medical professionals to diagnose and treat health conditions such as heart disease and cancer. Medical isotopes are produced using two overarching technologies: nuclear reactors and particle accelerators. There are currently global constraints on the supply of medical isotopes, and according to the government, the CMIE will ensure that Canada remains at the forefront of nuclear medicine innovation.

Swim advisory posted for popular Barrie beach due to high bacteria levels
Swim advisory posted for popular Barrie beach due to high bacteria levels

CTV News

time18 minutes ago

  • CTV News

Swim advisory posted for popular Barrie beach due to high bacteria levels

A swim advisory is in effect at Centennial Beach after water test results raised concerns about safety. The Simcoe Muskoka District Health Unit issued the recommendation based on samples taken on Monday, indicating significant bacteria levels. An advisory is a warning to swimmers, but not a beach closure. Advisories are issued when the bacteria levels exceed those considered safe by the health unit. City staff have posted advisory signs, warning visitors to avoid swimming until further notice. Additional water samples are being taken Monday, and the city says it will provide an update as soon as new results are available from public health officials.

Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes
Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes

Globe and Mail

timean hour ago

  • Globe and Mail

Health Canada approves Ozempic to reduce kidney decline in people with Type 2 diabetes

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes. Between 30 and 50 per cent of people with Type 2 diabetes develop some form of chronic kidney disease. An international clinical trial, called FLOW, showed the risk of kidneys significantly deteriorating or failing was 24 per cent lower in patients taking Ozempic compared to those taking a placebo injection. The patients taking the drug were also less likely to die from cardiovascular disease – another condition that affects many patients with diabetes. The study, funded by Ozempic manufacturer Novo Nordisk, was peer-reviewed and published in the New England Journal of Medicine last year and contributed to Health Canada's decision. Generic version of Ozempic, Wegovy to launch in Canada by Hims & Hers Dr. David Cherney, a nephrologist at Toronto General Hospital, helped lead the Canadian part of the trial and says the results show it's possible to reduce the loss of kidney function before patients need dialysis or a kidney transplant. 'What my patients are scared of is dialysis – dialysis or a transplant,' said Cherney, who is also a senior scientist at the Toronto General Hospital Research Institute, in an interview. 'I can reasonably reduce that risk and thereby reduce their anxiety and fear of serious, serious complications. Not to mention all the cardiovascular disease, which patients are also extremely afraid of.' Dr. Ehud Ur, an endocrinologist in Vancouver who was not involved in the study, said the results are credible and that Health Canada's approval of Ozempic to help prevent kidney decline is 'great news.' 'The prevention of kidney disease is a very important goal in the management of patients with Type 2 diabetes and this is another tool,' said Ur, who is a professor of endocrinology and metabolism at the University of British Columbia. Ozempic is the brand name of an injectable dose of semaglutide, a glucagon-like peptide-1 (GLP-1) hormone. Ozempic was first approved in Canada as a diabetes medication because it reduces blood sugar. It can also decrease appetite and has been approved as a weight-loss drug for people with obesity at a higher dose under the brand name Wegovy, which is also manufactured by Novo Nordisk. In an e-mail, Health Canada confirmed to The Canadian Press that on Aug. 13, it had approved Ozempic 'to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease and cardiovascular death in adults with Type 2 diabetes and chronic kidney disease.' Glomerular filtration rate is a measure that shows how well the kidneys are filtering out waste and excess water. Semaglutide, or Ozempic, reduces symptoms of feared diabetes complication, study finds Ozempic is the first GLP-1 drug approved in Canada to protect both kidneys and the heart in patients with Type 2 diabetes, said Ur, noting that the cardiovascular benefits of semaglutide have been extensively studied. 'The benefit of Ozempic is that you also get weight loss, which is a very important goal for most people (with Type 2 diabetes). That's a very exciting combination,' he said. Some people experience gastrointestinal side effects when they take Ozempic, Ur said, including nausea, vomiting, constipation and diarrhea. More severe complications can include gall bladder inflammation and pancreatitis, but most side effects are minor, he said. The benefit of slowing or stopping progressive kidney disease in people with diabetes would outweigh the risks of minor side effects, Ur said. The FLOW trial was conducted in 28 countries, including Canada. The researchers randomized 3,533 people with diabetes and chronic kidney disease to either receive Ozempic or a placebo. The study was conducted between 2019 and early 2024. Participants were followed for an average of 3.4 years to monitor for 'major kidney disease events,' including kidney failure leading to dialysis or transplantation, a 50-per-cent reduction in kidney function measured by glomerular filtration rate, or death from kidney-related or cardiovascular causes. The Ozempic or placebo doses were given to participants on top of other medications they were taking, including drugs to control blood pressure and blood sugar. Although reducing blood pressure and blood sugar have beneficial effects for the kidneys, Cherney said Ozempic appeared to have an additional positive impact on kidney function and future research can help pinpoint how that works. 'Another weapon against kidney disease is incredibly powerful. And these medicines will often turn patients around who are doing very poorly because it addresses so many different issues – the kidney, the cardiovascular, the metabolic, and the weight,' said Cherney. Ur said it's possible Ozempic could play a role in reducing inflammation in the kidneys and that might be one explanation for its positive effect. Regardless of the reason for its effectiveness, he said the FLOW trial and Health Canada's approval reinforces the importance of using the drug 'relatively early in the disease process' to minimize kidney damage in people with Type 2 diabetes.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store